Boston Scientific Corporation $BSX Position Cut by Courier Capital LLC

Courier Capital LLC decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 54.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,570 shares of the medical equipment provider’s stock after selling 19,934 shares during the quarter. Courier Capital LLC’s holdings in Boston Scientific were worth $723,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of BSX. GraniteShares Advisors LLC lifted its position in Boston Scientific by 1.5% in the 1st quarter. GraniteShares Advisors LLC now owns 13,599 shares of the medical equipment provider’s stock valued at $853,000 after purchasing an additional 195 shares during the last quarter. Avantax Planning Partners Inc. raised its holdings in shares of Boston Scientific by 4.0% during the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after buying an additional 201 shares during the last quarter. WPG Advisers LLC grew its holdings in Boston Scientific by 11.9% in the 1st quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock worth $120,000 after buying an additional 203 shares in the last quarter. Natural Investments LLC grew its holdings in Boston Scientific by 1.3% in the 2nd quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after buying an additional 206 shares in the last quarter. Finally, 180 Wealth Advisors LLC grew its holdings in Boston Scientific by 3.6% in the 1st quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock worth $406,000 after buying an additional 223 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of analyst reports. Piper Sandler reduced their price target on Boston Scientific from $65.00 to $60.00 in a research report on Wednesday, July 29th. Raymond James Financial reissued an “outperform” rating and set a $57.00 price target (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. TD Cowen restated a “buy” rating on shares of Boston Scientific in a research note on Thursday, September 17th. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $60.00 price objective (down from $75.00) on shares of Boston Scientific in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.43.

Insider Buying and Selling

In other Boston Scientific news, Director David Habiger purchased 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Mahoney purchased 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 194,522 shares of company stock valued at $9,385,210 over the last three months. Company insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX traded down $0.51 on Tuesday, reaching $43.33. 14,273,273 shares of the stock traded hands, compared to its average volume of 18,649,461. The firm’s fifty day simple moving average is $46.47 and its 200 day simple moving average is $50.35. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market cap of $62.79 billion, a price-to-earnings ratio of 17.54, a P/E/G ratio of 1.03 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $41.38 and a 12 month high of $105.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm earned $0.75 EPS. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.25 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.